STRATA Skin Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
March 13, 2024 08:00 ET
|
STRATA Skin Sciences, Inc.
HORSHAM, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and...
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
March 13, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports Full Year 2023 Financial Results and Corporate Developments
Dermatology Imaging Devices Market Report 2024, with Profiles of FotoFinder, e-con, Longport, Cortex Technology, VisualSonics, Clarius, Koninklijke Philips, Caliber Imaging and Diagnosis & DermLite
March 12, 2024 13:44 ET
|
Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Imaging Devices Market Size, Share & Trends Analysis Report By Modality (Digital Photographic Imaging, OCT, Dermatoscope, High...
Global Photodynamic Therapy Devices Market Report 2024: Analysis of Products, Applications, End-users and Regional Dynamics to 2034 Featuring Coherent Corp, Biolitec, & Lumibird Medical Among Other Key Players
March 11, 2024 14:11 ET
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Photodynamic Therapy Devices Market Analysis & Forecast to 2024-2034: Market By Product; By Application; By End-user; and By Region" report...
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
March 11, 2024 08:30 ET
|
Journey Medical Corporation
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with...
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
March 09, 2024 12:00 ET
|
Alumis Inc
Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024.
SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555
March 07, 2024 16:35 ET
|
SkinCure Oncology LLC
BURR RIDGE, Ill., March 07, 2024 (GLOBE NEWSWIRE) -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy...
STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage
March 07, 2024 08:00 ET
|
STRATA Skin Sciences, Inc.
HORSHAM, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and...
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting
February 29, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Preclinical Research on Full-Thickness Cutaneous Wound Healing KNOXVILLE, TN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB:...
Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases
February 27, 2024 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin...